BACKGROUND: Extranodal natural killer T-cell lymphoma, nasal-type (NKTCL), is a rare malignancy in Western populations and is thus challenging for standardization of care and a prospective study. This study was aimed at defining patterns of care for NKTCL in the context of radiotherapy (RT) use and dose selection in the United States. METHODS: Six hundred forty-two stage I-II NKTCL patients from 1998 to 2012 were identified from the National Cancer Data Base. Binary logistic regression analyses were performed to identify sociodemographic, treatment, and tumor characteristics predictive of the treatment selection and RT dose. Overall survival (OS) analyses were completed with the Kaplan-Meier and Cox multivariate methods, including a propensity score adjustment for a potential indication bias. RESULTS: Of the 642 included NKTCL patients, 70% were at stage I, 79% were white, and 66% were 60 years old. Fifty-five percent received chemotherapy plus RT, 19% received RT alone, and 27% received chemotherapy alone. The median RT dose was 50 Gy (interquartile range, 43.2-54 Gy), 37% received < 45 Gy, and 43% received < 50 Gy. A multivariate survival analysis showed improved OS in comparison with chemotherapy alone for RT alone at 50 Gy (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.23-0.70; P <.01), for chemotherapy plus RT at <50 Gy (HR, 0.55, 95% CI, 0.36-0.86; P <.01), and for chemotherapy plus RT at 50 Gy (HR, 0.41; 95% CI, 0.27-0.63; P <.01). CONCLUSIONS: Stage I-II NKTCL patients in the United States commonly receive chemotherapy alone or suboptimal-dose RT. The omission of RT or the use of suboptimal RT is negatively associated with OS. Efforts to continue improving evidenced-based management are warranted. Cancer 2017;123:3176-85.
INTRODUCTION
Extranodal natural killer T-cell lymphoma, nasal type (NKTCL), is a rare subtype of non-Hodgkin lymphoma (NHL) characterized by aggressive, localized angio-invasion and strongly associated with an Epstein-Barr virus infection. 1 NKTCL, now recognized in the 2016 World Health Organization classification separately from peripheral T-cell lymphoma as another type of mature T and natural killer neoplasm, accounts for approximately 20% of T-cell NHL cases in Asian populations but represents 5% in Western populations. 2 The low incidence of NKTCL even in endemic populations has challenged treatment standardization, with current treatment approaches loosely defined and based on the limited available data, which predominantly come from Asia.
The treatment principles for NKTCL that are defined are largely unique among NHLs. Anthracycline-based regimens common to NHL, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, are generally considered suboptimal systemic therapies. 3 Locally invasive, early-stage NKTCL represents the majority of cases, and a number of series have highlighted the importance of radiotherapy (RT) dose-escalated to doses 50 to 54 Gy, 4, 5 which are significantly higher than the 24-to 40-Gy RT dose range used for most NHLs. 6 Moreover, in comparison with the more standard role of consolidative RT after chemotherapy for aggressive NHL, 7 early upfront integration of RT may yield better survival for patients with NKTCL. 5, 8 There exists significant heterogeneity in international clinical practice guideline recommendations for the optimal management of NKTCL. For instance, the 2016 National Comprehensive Cancer Network guidelines support combination chemotherapy with a number of aggressive ifosfamide-or L-asparaginase-based regimens plus RT delivered in a concurrent, sandwich, or sequential fashion, with RT alone reserved for patients unfit for chemotherapy. 9 Conversely, the International Lymphoma Radiation Oncology Group guidelines recognize RT alone as an acceptable treatment strategy and question the comparative benefit of the addition of chemotherapy. 10 Finally, the European Society of Medical Oncology guidelines take a more neutral stance and recommend that "if feasible, radiation with or without chemotherapy seems to be a more effective treatment compared with chemotherapy alone." 11 Moreover, these clinical practice guidelines are relatively new. The International Lymphoma Radiation Oncology Group guidelines were just recently published in 2015. The first European Society of Medical Oncology guidelines for peripheral T-cell lymphoma were published in 2013 after a consensus conference was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland. The first complete library of the National Comprehensive Cancer Network guidelines was made public in December 2001.
With its uncommon incidence, its unusual management principles, and the discordance in evolving clinical practice guideline recommendations, we hypothesize that significant heterogeneity may exist in the management of early-stage NKTCL in the United States, and we attempt to assess how patterns of treatment selection in NKTCL affect overall survival (OS) in a Western population.
MATERIALS AND METHODS
A US hospital-based registry analysis was performed retrospectively with the National Cancer Data Base (NCDB). The NCDB is a de-identified registry (thus exempt from institutional review board oversight) jointly maintained by the American College of Surgeons and the American Cancer Society; it captures more than 70% of new cancer diagnoses in the United States at more than 1500 Commission on Cancer-accredited institutions. A Consolidated Standards of Reporting Trials diagram describing the cohort selection is outlined in Figure 1 Race was categorized as a categorical variable with the 3 most commonly included races-white, Asian, and African American-plus the other category for the remaining 1% not captured by the 3 most common races. The previously defined Charleston Deyo comorbidity index was used to quantify patient comorbidity. 12 The insurance category was defined on the basis of the insurance type from the admission page. Education represented the number of adults in the patient's zip code who did not complete a high school education according to the year 2000 US Census data. The treatment facility type represented the classification of the Commission on Cancer Accreditation. The facility location was defined with the US Department of Agriculture Economic Research Service typology. Income was estimated against files derived from year 2000 US Census data for the patient's zip code at diagnosis. An age at diagnosis 60 years was categorized in agreement with a previously defined prognostic cutoff for NKTCL. 13 The stage was based on American Joint Committee on Cancer staging for the reported pathologic stage group if the pathologic stage was reported; if not, then the reported clinical stage group was used. The distance from the treatment facility was grouped around the median value. Early RT versus delayed RT was defined with a cutoff of 67 days in an attempt to capture RT that started within the first chemotherapy cycle; this was calculated by the addition of 4 weeks to the median time to the initiation of chemotherapy for patients receiving chemotherapy plus RT. 5 The RT dose, calculated as the sum of both the regional and boost doses, was categorized as 50.0 Gy because this dose represents the median dose herein and the minimum recommended dose in some clinical practice guidelines. 10, 11 To further assess the potential impact of the RT dose selection, we also examined doses 45.0 Gy because we recognized that excellent outcomes have been published with 45 Gy and with asparaginase-containing regimens and dose ranges recommended in other guidelines. 9, 11 Statistical analyses were completed with SPSS 23 (IBM Corp, Armonk, NY). Both univariate and multivariate bivariate logistic regression analyses were used to assess the association between sociodemographic, treatment, and tumor characteristics and treatment selection. OS was calculated with the Kaplan-Meier method from the date of diagnosis to the date of last contact or death. Log-rank statistics were used to test whether a statistically significant difference existed in the cumulative proportions between the groups. A Cox proportional hazards model was used for the multivariate survival analysis and was formed in a hierarchical fashion with backward selection of the covariates' likelihood ratios. To confirm the assumption of appropriateness, the proportional hazards assumption over time for each covariate in the Cox proportional hazards model was tested graphically with loglog survival functions. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) are reported. For all analyses, an a value of .05 was used to indicate statistical significance. A propensity score analysis was conducted to account for a potential indication bias, with propensity scores calculated on the basis of a forced-entry multivariate logistic regression analysis for all observed covariates Original Article generating a score reflective of the conditional probability of treatment selection. The propensity score was incorporated with treatment selection with the Cox method as a continuous covariate. The assumption of balance between the groups was confirmed by stratification into quintiles by the propensity score; this confirmed that the standardized difference was <0.10. To further assess the strength of the findings, sensitivity analyses were completed that excluded covariates with >5% of the values missing (B symptoms and comorbidity score) or a time bias (year of diagnosis and time to RT initiation). Finally, to account for a potential immortal time bias, survival analyses were repeated with a 3-month conditional landmark. Gy. Eighteen of the 389 patients with a recorded RT dose (5%) received < 40 Gy, with only 3% (n 5 13) receiving < 25 Gy; 37% received < 45 Gy, and 43% received < 50 Gy. Intensity-modulated radiotherapy (IMRT) was used for 36% of the combined-modality group, and this rate significantly increased from 0% in 1998 to a peak of 60% in 2011 (P < .0001); for the RTalone group, IMRT was used in 28%, with no significant difference in utilization over time (0% in 1998 vs 50% in 2012; P 5 .29). A univariate analysis comparing the treatment selection of chemotherapy alone versus chemotherapy plus RT suggested increased use of combined-modality therapy in Asian patients and with increasing education quartiles (see Supporting Table 1 [see online supporting information]); however, in a multivariate analysis, no significant predictors for the use of combined-modality therapy over chemotherapy alone were identified. A univariate analysis comparing the selection of the combined modality versus RT alone suggested decreased use of the combined modality with increasing comorbidity scores, government insurance, decreasing education, older age, and stage I (see Supporting Table 2 [see online supporting information]); however, in a multivariate analysis, the only factor significantly influencing the selection of the combined modality was older age (odds ratio [OR], 0.36; 95% CI, 0.21-0.62; P < .01). A univariate analysis comparing the selection of chemotherapy alone versus RT alone suggested decreasing use of RT alone with younger age, nongovernment insurance, and stage II (see Supporting Table 3 [see online supporting information]); however, in a multivariate analysis, only older age (OR, 3.87; 95% CI, 2.30-6.50; P < .01) and stage II (OR, 0.32; 95% CI, 0.17-0.59; P < .01) significantly affected the use of RT alone. The selection of an RT dose < 50 Gy was significantly influenced by the year of diagnosis, IMRT, and the timing of RT (early vs delayed) in a univariate analysis (see Supporting Table 4 [see online supporting information]); however, in a multivariate analysis, only the delayed initiation of RT remained a significant negative predictor for an RT dose 50 Gy with an OR of 0.38 (95% CI, 0.23-0.63; P < .01), and the use of IMRT remained a positive predictor for a dose 50 Gy with an OR of 1.66 (95% CI, 1.05-2.62; P < .03). The selection of an RT dose 45 Gy was significantly influenced by the year of diagnosis, IMRT, timing of RT (early vs delayed), and age in a univariate analysis (see Supporting Table 5 [see online supporting information]); however, in a multivariate analysis, only a later year of diagnosis remained a significant positive predictor for an RT dose 45 Gy with an OR of 3.27 (95% CI, 1.09-9.82; P 5 .04) for 2003-2007 and with an OR of 4.36 (95% CI, 1.46-13.01; P < .01) for 2008-2012 versus 1998-2002, and an older age was a negative predictor for a dose 45 Gy with an OR of 0.54 (95% CI, 0.33-0.87; P 5 .01). Figure 2 summarizes the temporal trends in treatment selection and RT dose over time.
RESULTS
The median follow-up was 21 months (interquartile range, 7-56 months) for all patients and 48 months Models formed with stepwise backward elimination are presented.
Treatment Selection for NK T-Cell Lymphoma/Vargo et al
Cancer August 15, 2017 (interquartile range, 25-79 months) for surviving patients. There were 284 deaths in all in the entire cohort. The 5-year OS was 45% (95% CI, 35%-55%) for RT alone, 32% (95% CI, 24%-40%) for chemotherapy alone, and 58% (95% CI, 52%-64%) for the combined modality (P < .01; see Fig. 3A ). The following factors in addition to treatment selection were identified to be significant predictors of OS in the univariate analysis: private insurance, age 60 years, absence of B symptoms, and stage I (vs II). The multivariate survival analysis confirmed the treatment effect over chemotherapy alone with an HR for death of 0.54 (95% CI, 0.35-0.83; P < .01) for RT alone and with an HR for death of 0.47 (95% CI, 0.33-0.67; P < .01) for chemotherapy plus RT (see Table 2 and Fig.  3B ). No significant difference in OS was seen for the combined modality versus RT alone in the multivariate analysis. The propensity score-adjusted multivariate analysis confirmed the OS advantage associated with RT alone versus chemotherapy alone (HR, 0.46; 95% CI, 0.27-0.76; P 5 .02; see Fig. 3C ), with the results also confirmed by a 3-month conditional landmark analysis. Similarly, the propensity score-adjusted multivariate analysis confirmed the OS advantage associated with chemotherapy plus RT versus chemotherapy alone (HR, 0.48; 95% CI, 0.32-0.71; P < .01; see Fig. 3D ), with the results also confirmed by a 3-month conditional landmark analysis. Overall survival probabilities by treatment selection, including the radiotherapy dose, in a multivariate analysis using (A) a 50-Gy cutoff and (B) a 45-Gy cutoff, (C) in a propensity score analysis using a 50-Gy cutoff, and (D) in a propensity score analysis using a 45-Gy cutoff.
This was confirmed by sensitivity analyses excluding time-biased covariates and covariates with >5% of the values missing.
The 5-year OS was 32% (95% CI, 24%-40%) for chemotherapy alone, 38% (95% CI, 22%-54%) for RT alone at <50 Gy, 52% (95% CI, 36%-68%) for RT alone at 50 Gy, 53% (95% CI, 43%-63%) for chemotherapy plus RT at <50 Gy, and 62% (95% CI, 53%-70%) for chemotherapy plus RT at 50 Gy (P < .01). The 5-year OS was 32% (95% CI, 24%-40%) for chemotherapy alone, 24% (95% CI, 6%-42%) for RT alone at <45 Gy, 54% (95% CI, 40%-67%) for RT alone at 45 Gy, 51% (95% CI, 39%-63%) for chemotherapy plus RT at <45 Gy, and 61% (95% CI, 53%-69%) for chemotherapy plus RT at 45 Gy (P < .01). The multivariate analysis confirmed the OS advantage associated with an RT dose 50 Gy (see Table 2 and Fig. 4A ) and with an RT dose 45 Gy (see Table 2 and Fig. 4B ) over chemotherapy alone, regardless of the integration of chemotherapy with RT; there was no difference in OS between RT alone at <45 Gy or RT alone at <50 Gy and chemotherapy alone. Propensity score analyses confirmed the OS advantage associated with an RT dose 50 Gy (HR, 0.52; 95% CI, 0.34-0.79; P < .01; see Fig. 4C ); including 3-month conditional landmark and sensitivity analyses excluding timebiased and incomplete covariates except when all the time-biased and incomplete covariates were removed from the propensity score. Propensity score analyses confirmed the OS advantage associated with an RT dose 45 Gy (HR, 0.42; 95% CI, 0.27-0.64; P < .01; see Fig. 4D ); including 3-month conditional landmark and sensitivity analyses excluding time-biased and incomplete covariates.
DISCUSSION
In this large hospital-based registry analysis of NKTCL in a nonendemic, predominantly white population, twothirds of the 642 included stage I-II NKTCL patients received chemotherapy alone or RT doses less than those recommended in clinical practice guidelines; trends appear to have been improving (see Fig. 2 ), though not to a consistent level of statistical significance, from 1998 to 2012. [9] [10] [11] Combined-modality therapy and RT doseescalated to 45 to 50 Gy, as recommended in clinical practice guidelines, were associated with improved OS, even after adjustments for observable confounding variables in the multivariate analysis. Although the ideal treatment approach to NKTCL has remained controversial, the results of this study suggest that deviations from clinical practice guideline recommendations, including the omission of RT and suboptimal RT delivery, are common in United States, and these deviations may negatively affect OS.
Prospective comparative outcome analyses to guide treatment selection are currently lacking for stage I-II NKTCL; however, National Comprehensive Cancer Network, European Society of Medical Oncology, and International Lymphoma Radiation Oncology Group guidelines do not support the use of chemotherapy alone. [9] [10] [11] Despite this, 27% of the patients from 1998 to 2012 included herein from the NCDB received chemotherapy alone, and this resulted in an estimated 5-year OS rate of 32% versus 58% with combined-modality therapy. These results are highly consistent with a recently reported multicenter study from 10 Chinese institutions with 1273 stage I-II NKTCL patients, in which combined-modality therapy was significantly more effective than chemotherapy alone with a 5-year OS rate of 67% for combinedmodality therapy versus 33% for chemotherapy alone. 14 Others have similarly shown a consistent doubling in 3-year OS from 30% to 57% for chemotherapy alone versus combined-modality therapy in predominantly endemic Asian populations. 2 The congruency between these Asian studies and the results reported herein for a sample that was 79% white suggests that in agreement with smaller retrospective, single-institution studies, the treatment rules defined for endemic populations, including the importance of dose-escalated RT, remain true for nonendemic, predominantly white populations with NKTCL. 15, 16 Although the estimated 5-year OS rate of 62% for the best-treatment group, chemotherapy plus RT at 50 Gy, was improved in comparison with the rates with chemotherapy alone and chemotherapy plus RT at <50 Gy herein, recent phase 2 trials have suggested comparatively superior 2-to 5-year OS rates of 73% to 89% for Lasparaginase-or ifosfamide-based combined chemotherapy regimens plus RT. [17] [18] [19] [20] Ideally, international clinical practice guidelines would incorporate these more aggressive combination chemotherapy regimens. 9, 11 Unfortunately, because of limitations of the NCDB, we were unable to integrate the chemotherapy type or the number of cycles used into the analysis. Although the majority of these aggressive combination chemotherapy regimens continue to use higher RT doses ranging from 50 to 56 Gy, [18] [19] [20] some incorporate potent radiation-sensitizing chemotherapy concurrently with RT and thus have lowered the dose of RT to 40 to 52.8 Gy with comparable outcomes. 17 Again, we were unable capture the impact of the chemotherapy type on the RT dose selection.
However, interestingly, the delayed integration of RT with chemotherapy herein was negatively associated with an RT dose selection 50 Gy, and this suggests that concurrent integration of RT with more aggressive systemic therapy may not account for the lower RT dose selection seen herein. Early integration of RT has been shown to be an important predictor of outcomes in NKTCL; however, this was not confirmed in the current analysis. 5, 8 A number of prior series have suggested the importance of RT doses 50 Gy. 4, 5 Despite this, 37% of patients with a recorded RT dose received <45 Gy, and 43% received < 50 Gy. IMRT has clearly been shown to widen the therapeutic ratio in the treatment of carcinomas of the nasopharynx over conventional RT. 21 IMRT was increasingly used over time in this study; and the use of IMRT correlated with the selection of higher RT doses 45 Gy. Others have suggested the potential impact of IMRT on improving outcomes in lymphoma. 22 The adoption of modern RT techniques such as IMRT may promote increased evidence-based integration of RT doses 45 to 50 Gy by widening the therapeutic ratio. One potential criticism of the dose response examined herein is that patients unable to complete RT were biased to be within the <45-to 50-Gy cohort; however, only 5% (n 5 18) received < 40 Gy, and 3% (n 5 13) received < 25 Gy. Thus, the number of patients this potentially represents is small. The utilization of lower RT doses transcended factors previously shown to influence modern treatment selection in lymphomas, such as academic treatment centers versus community treatment centers, treatment facility location, patient race, patient comorbidity, patient insurance, and stage. 23, 24 Importantly, as highlighted in Figure 2 , these trends seem to be improving over time with increasing utilization of higher RT doses over time.
OS was similarly significantly improved for patients of a younger age and for patients with stage I disease (vs II disease). Others have previously shown the prognostic significance of age and stage in NKTCL. 13, 14 A combination of these prognostic factors, plus other unobservable and potentially confounding variables (eg, the lactate dehydrogenase level, performance status, and extent of primary tumor invasion), may help to risk-stratify NKTCL patients and identify a good-prognosis subgroup for which RT alone can achieve excellent outcomes.
14 Current clinical practice guidelines are incongruent when it comes to recommendations regarding the appropriateness of RT alone. [9] [10] [11] Although some studies have suggested higher rates of late recurrences with RT alone, 25, 26 others have suggested, as documented herein, that dose-escalated RT alone can be a highly effective treatment modality for early-stage NKTCL and should be preferred whenever a single modality is being considered over chemotherapy alone. 5, 14 This analysis calls into question the comparative benefits of adding chemotherapy to dose-escalated RT (see Fig. 4) ; this finding has been previously suggested by other NKTCL data. 27 However, as previously mentioned, because of limitations of the NCDB, we were unable to capture the specific chemotherapy type, and thus, it is unclear whether this holds true for modern combinedmodality regimens. [17] [18] [19] [20] Additional limitations of our study include a potential ascertainment bias, a selection bias, and missing registry data (eg, B symptoms, which were unrecorded for 30%), although we attempted to account for some of these potential biases with sensitivity analyses and propensity score adjustments as much as possible within the limitations of the NCDB.
In conclusion, despite international practice guidelines advocating combined-modality therapy or RT alone and a minimum RT dose of 45 to 50 Gy, more than twothirds of stage I-II NKTCL patients in this US hospitalbased registry analysis with known/coded information received no RT or RT doses < 45 to 50 Gy; these trends appear to be improving over time, though not to a consistent level of statistical significance. The omission of RT or a suboptimal RT dose is negatively associated with OS, and this highlights the integral role of dose-escalated RT in the management of NKTCL in a Western population. Because of the inconsistencies in treatment selection with respect to clinical practice guidelines and the negative association with OS, increased efforts to improve education and evidence-based management of NKTCL are warranted.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
John A. Vargo reports speaking honoraria from Brainlab.
AUTHOR CONTRIBUTIONS
John A. Vargo: Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Arisha Patel: Conceptualization, methodology, validation, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Scott M. Glaser: Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Goundappa K. Balasubramani: Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Rafic J. Farah: Conceptualization, methodology, validation, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Stanley M. Marks: Conceptualization, methodology, validation, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration. Sushil Beriwal: Conceptualization, methodology, software, validation, formal analysis, investigation, data curation, writing (original draft), writing (review and editing), visualization, supervision, and project administration.
